Pathway / Mechanism Diagram
flowchart TD
A["Genetic<br/>Risk Factors"] --> B["Molecular<br/>Pathology"]
A0["MSA"] --> A
A1["SDS"] --> A
B --> D["Cellular<br/>Dysfunction"]
D --> E["Neuroinflammation"]
E --> F["Neuronal<br/>Damage"]
F --> G["Clinical<br/>Symptoms"]
H["Therapeutic<br/>Interventions"] -.->|"target"| BOverview
Shy-Drager syndrome (SDS) is a rare neurodegenerative disorder characterized by progressive autonomic failure in conjunction with parkinsonian features consistent with Parkinson’s disease. It is now classified as a variant of multiple system atrophy (MSA), specifically the MSA-A (autonomic) subtype. The syndrome represents an important historical entity that helped establish the concept of oligodendroglial cytoplasmic inclusions and α-synuclein pathology in neurodegenerative disease1Graham JG, Oppenheimer DR. Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy. J Neurol Neurosurg Psychiatry. 1969Open reference.
History
The identification of Shy-Drager syndrome was a landmark in understanding autonomic failure and neurodegenerative disease2Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. Arch Neurol. 1960;2(5):511-527Open reference:
-
1960: Milton Shy and Glenda Drager described a syndrome of autonomic failure with parkinsonism3Shy GM, Drager GA. Original description (1960)Open reference
-
1969: The term “Shy-Drager syndrome” came into common use following detailed clinical descriptions4Bannister R, Oppenheimer DR. Degenerative diseases of the nervous system. Brain. 1972Open reference
-
1989: Multiple system atrophy (MSA) was proposed as an umbrella term encompassing Shy-Drager syndrome, striatonigral degeneration, and olivopontocerebellar atrophy5Graham JG, Oppenheimer DR. MSA terminology (1989)Open reference
-
1998: Discovery of α-synuclein in glial cytoplasmic inclusions established the proteinaceous basis of MSA6α-Synuclein in filamentous inclusions of MSA. Nature. 1997Open reference
-
2008: Second consensus criteria for MSA established modern diagnostic framework7Second consensus statement on MSA. Neurology. 2008Open reference
Clinical Features
Autonomic Dysfunction
Autonomic failure is the defining feature of Shy-Drager syndrome8MSA: autonomic features. Neurol Clin. 2015Open reference:
Cardiovascular:
-
Orthostatic hypotension (significant drop in blood pressure upon standing, >20 mmHg systolic or >10 mmHg diastolic)9Freeman R. Orthostatic hypotension in MSA. Clin Auton Res. 2008Open reference
-
Postprandial hypotension10Postprandial hypotension in autonomic disorders. Clin Auton Res. 2015Open reference
-
Supine hypertension2Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. Arch Neurol. 1960;2(5):511-527Open reference0
-
Reduced heart rate variability2Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. Arch Neurol. 1960;2(5):511-527Open reference1
Urinary:
-
Urinary urgency, frequency, and nocturia2Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. Arch Neurol. 1960;2(5):511-527Open reference2
-
Urinary hesitancy and retention2Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. Arch Neurol. 1960;2(5):511-527Open reference3
-
Incomplete bladder emptying2Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. Arch Neurol. 1960;2(5):511-527Open reference4
-
Detrusor overactivity followed by detrusor underactivity2Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. Arch Neurol. 1960;2(5):511-527Open reference5
Sexual:
-
Erectile dysfunction (almost universal in males)2Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. Arch Neurol. 1960;2(5):511-527Open reference6
-
Reduced libido2Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. Arch Neurol. 1960;2(5):511-527Open reference7
Gastrointestinal:
-
Severe constipation (very common)2Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. Arch Neurol. 1960;2(5):511-527Open reference8
-
Dysphagia and odynophagia2Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. Arch Neurol. 1960;2(5):511-527Open reference9
-
Gastroparesis3Shy GM, Drager GA. Original description (1960)Open reference0
-
Fecal incontinence (late stage)3Shy GM, Drager GA. Original description (1960)Open reference1
Thermoregulatory:
-
Reduced sweating (anhidrosis)3Shy GM, Drager GA. Original description (1960)Open reference2
-
Cold, mottled hands and feet3Shy GM, Drager GA. Original description (1960)Open reference3
-
Heat intolerance3Shy GM, Drager GA. Original description (1960)Open reference4
Parkinsonian Features
Motor symptoms resemble idiopathic Parkinson’s disease but with important distinctions3Shy GM, Drager GA. Original description (1960)Open reference5:
Core Symptoms:
-
Bradykinesia (slowness of movement)3Shy GM, Drager GA. Original description (1960)Open reference6
-
Rigidity (cogwheel or lead-pipe)3Shy GM, Drager GA. Original description (1960)Open reference7
-
Resting tremor (less common than in IPD)3Shy GM, Drager GA. Original description (1960)Open reference8
-
Postural instability (early and severe)3Shy GM, Drager GA. Original description (1960)Open reference9
-
Gait difficulty (shuffling, freezing)4Bannister R, Oppenheimer DR. Degenerative diseases of the nervous system. Brain. 1972Open reference0
Distinguishing Features:
-
Poor or absent levodopa response4Bannister R, Oppenheimer DR. Degenerative diseases of the nervous system. Brain. 1972Open reference1
-
Symmetric onset (vs. asymmetric in IPD)4Bannister R, Oppenheimer DR. Degenerative diseases of the nervous system. Brain. 1972Open reference2
-
Rapid progression4Bannister R, Oppenheimer DR. Degenerative diseases of the nervous system. Brain. 1972Open reference3
-
Early falls (within 3 years of onset)4Bannister R, Oppenheimer DR. Degenerative diseases of the nervous system. Brain. 1972Open reference4
Cerebellar Features
Some patients show cerebellar involvement4Bannister R, Oppenheimer DR. Degenerative diseases of the nervous system. Brain. 1972Open reference5:
-
Gait ataxia4Bannister R, Oppenheimer DR. Degenerative diseases of the nervous system. Brain. 1972Open reference6
-
Limb ataxia4Bannister R, Oppenheimer DR. Degenerative diseases of the nervous system. Brain. 1972Open reference7
-
Scanning speech4Bannister R, Oppenheimer DR. Degenerative diseases of the nervous system. Brain. 1972Open reference8
-
Nystagmus4Bannister R, Oppenheimer DR. Degenerative diseases of the nervous system. Brain. 1972Open reference9
-
Oculomotor abnormalities5Graham JG, Oppenheimer DR. MSA terminology (1989)Open reference0
Additional Neurological Signs
-
Stridor (in some cases, particularly during sleep)5Graham JG, Oppenheimer DR. MSA terminology (1989)Open reference1
-
Laryngeal stridor affecting speech5Graham JG, Oppenheimer DR. MSA terminology (1989)Open reference2
-
Dysarthria (hypokinetic, spastic, or ataxic)5Graham JG, Oppenheimer DR. MSA terminology (1989)Open reference3
-
Respiratory dysfunction (central or obstructive sleep apnea)5Graham JG, Oppenheimer DR. MSA terminology (1989)Open reference4
-
REM sleep behavior disorder5Graham JG, Oppenheimer DR. MSA terminology (1989)Open reference5
Pathology
Neuropathological Findings
The characteristic pathology of Shy-Drager syndrome reveals specific patterns of neurodegeneration5Graham JG, Oppenheimer DR. MSA terminology (1989)Open reference6:
Macroscopic Findings:
-
Atrophy of brainstem (particularly dorsal vagal nucleus)5Graham JG, Oppenheimer DR. MSA terminology (1989)Open reference7
-
Atrophy of the cerebellum and olivary nuclei5Graham JG, Oppenheimer DR. MSA terminology (1989)Open reference8
-
Atrophy of putamen (more severe in posterior portion)5Graham JG, Oppenheimer DR. MSA terminology (1989)Open reference9
-
Pallor of the substantia nigra and locus coeruleus6α-Synuclein in filamentous inclusions of MSA. Nature. 1997Open reference0
Microscopic Findings:
-
Neuronal loss and gliosis in autonomic nuclei6α-Synuclein in filamentous inclusions of MSA. Nature. 1997Open reference1
-
Dorsal motor nucleus of vagus6α-Synuclein in filamentous inclusions of MSA. Nature. 1997Open reference2
-
Nucleus tractus solitarius6α-Synuclein in filamentous inclusions of MSA. Nature. 1997Open reference3
-
Onuf’s nucleus (sacral spinal cord)6α-Synuclein in filamentous inclusions of MSA. Nature. 1997Open reference4
-
-
Degeneration of the intermediolateral cell column in the spinal cord (sympathetic preganglionic neurons)6α-Synuclein in filamentous inclusions of MSA. Nature. 1997Open reference5
-
Oligodendroglial cytoplasmic inclusions (GCIs) containing abnormal α-synuclein6α-Synuclein in filamentous inclusions of MSA. Nature. 1997Open reference6
-
Neuronal cytoplasmic inclusions (NCIs)[^58]
-
Glial nuclear inclusions (GNIs)6α-Synuclein in filamentous inclusions of MSA. Nature. 1997Open reference7
Biochemical Abnormalities
Neurotransmitter Deficits:
-
Reduced norepinephrine levels (sympathetic nervous system)6α-Synuclein in filamentous inclusions of MSA. Nature. 1997Open reference8
-
Reduced dopamine in striatum6α-Synuclein in filamentous inclusions of MSA. Nature. 1997Open reference9
-
Reduced serotonin in brainstem7Second consensus statement on MSA. Neurology. 2008Open reference0
-
Reduced GABA in cerebellum7Second consensus statement on MSA. Neurology. 2008Open reference1
Autonomic Function:
-
Impaired baroreflex sensitivity7Second consensus statement on MSA. Neurology. 2008Open reference2
-
Loss of catecholaminergic neurons in the locus coeruleus7Second consensus statement on MSA. Neurology. 2008Open reference3
-
Reduced plasma catecholamine response to tilting7Second consensus statement on MSA. Neurology. 2008Open reference4
Genetic Factors
While most cases are sporadic, genetic factors may contribute7Second consensus statement on MSA. Neurology. 2008Open reference5:
| Gene | Finding | Significance |
|---|---|---|
| SNCA | Rare variants | Suggests genetic contribution |
| COQ2 | Variants associated | Implicates coenzyme Q10 pathway |
| GIGYF2 | Variants in some families | Parkinsonism genes may modify |
| FBXO7 | Rare variants | Links to mitochondrial function |
Classification
Shy-Drager syndrome is now considered synonymous with Multiple System Atrophy - Autonomic type (MSA-A), one of two main subtypes of MSA7Second consensus statement on MSA. Neurology. 2008Open reference6:
| Subtype | Primary Features | Alternate Names |
|---|---|---|
| MSA-A (Shy-Drager) | Predominant autonomic failure | MSA with autonomic failure |
| MSA-P | Predominant parkinsonism | Striatonigral degeneration |
| MSA-C | Predominant cerebellar ataxia | Olivopontocerebellar atrophy |
The term “MSA” has largely replaced “Shy-Drager syndrome” in clinical practice because:
-
It encompasses the broader spectrum of clinical presentations7Second consensus statement on MSA. Neurology. 2008Open reference7
-
It reflects the common underlying α-synuclein pathology7Second consensus statement on MSA. Neurology. 2008Open reference8
-
It facilitates communication among clinicians and researchers7Second consensus statement on MSA. Neurology. 2008Open reference9
-
It allows for mixed phenotypes (MSA-A/P or MSA-A/C)8MSA: autonomic features. Neurol Clin. 2015Open reference0
Relationship to Multiple System Atrophy
Shy-Drager syndrome represents the autonomic-predominant variant of MSA8MSA: autonomic features. Neurol Clin. 2015Open reference1. The relationship is defined by:
Shared Pathology:
-
α-Synuclein positive glial cytoplasmic inclusions (GCIs)8MSA: autonomic features. Neurol Clin. 2015Open reference2
-
Oligodendroglial involvement (primary vs secondary)8MSA: autonomic features. Neurol Clin. 2015Open reference3
-
Distribution pattern determines clinical phenotype8MSA: autonomic features. Neurol Clin. 2015Open reference4
Clinical Overlap:
-
MSA-A and MSA-P share many features8MSA: autonomic features. Neurol Clin. 2015Open reference5
-
Autonomic failure can occur in MSA-P8MSA: autonomic features. Neurol Clin. 2015Open reference6
-
Parkinsonism can occur in MSA-A8MSA: autonomic features. Neurol Clin. 2015Open reference7
Diagnosis
Clinical Criteria
Current diagnostic criteria require combination of features8MSA: autonomic features. Neurol Clin. 2015Open reference8:
Definite MSA:
-
Autopsy confirmation with appropriate pathology8MSA: autonomic features. Neurol Clin. 2015Open reference9
Probable MSA:
-
Autonomic failure (orthostatic hypotension + urinary dysfunction)9Freeman R. Orthostatic hypotension in MSA. Clin Auton Res. 2008Open reference0
-
Plus parkinsonism poorly responsive to levodopa OR cerebellar ataxia9Freeman R. Orthostatic hypotension in MSA. Clin Auton Res. 2008Open reference1
Possible MSA:
-
Autonomic failure OR parkinsonism/ataxia plus additional features9Freeman R. Orthostatic hypotension in MSA. Clin Auton Res. 2008Open reference2
-
MRI abnormalities supporting the diagnosis9Freeman R. Orthostatic hypotension in MSA. Clin Auton Res. 2008Open reference3
Supporting Findings
Neuroimaging:
-
MRI: Atrophy of brainstem, cerebellum, putamen, and middle cerebellar peduncle9Freeman R. Orthostatic hypotension in MSA. Clin Auton Res. 2008Open reference4
-
Hot cross bun sign in pons on T2-weighted MRI9Freeman R. Orthostatic hypotension in MSA. Clin Auton Res. 2008Open reference5
-
T2 hypointensity in putamen with lateral rim hyperintensity9Freeman R. Orthostatic hypotension in MSA. Clin Auton Res. 2008Open reference6
-
Diffusion-weighted imaging: increased ADC in putamen and cerebellum9Freeman R. Orthostatic hypotension in MSA. Clin Auton Res. 2008Open reference7
-
PET/SPECT: Reduced striatal dopamine transporter binding9Freeman R. Orthostatic hypotension in MSA. Clin Auton Res. 2008Open reference8
Autonomic Testing:
-
Abnormal baroreflex function (reduced baroreflex gain)9Freeman R. Orthostatic hypotension in MSA. Clin Auton Res. 2008Open reference9
-
Impaired heart rate variability10Postprandial hypotension in autonomic disorders. Clin Auton Res. 2015Open reference0
-
Abnormal thermoregulatory sweat test10Postprandial hypotension in autonomic disorders. Clin Auton Res. 2015Open reference1
-
Bladder function studies10Postprandial hypotension in autonomic disorders. Clin Auton Res. 2015Open reference2
Laboratory:
-
CSF biomarkers under investigation10Postprandial hypotension in autonomic disorders. Clin Auton Res. 2015Open reference3
-
Reduced norepinephrine response to standing10Postprandial hypotension in autonomic disorders. Clin Auton Res. 2015Open reference4
Differential Diagnosis
Conditions to exclude or distinguish:
| Condition | Distinguishing Features |
|---|---|
| Idiopathic Parkinson’s Disease | Asymmetric onset, levodopa response, no autonomic failure early |
| Dementia with Lewy Bodies | Cognitive fluctuations, visual hallucinations |
| Pure Autonomic Failure | No parkinsonism or cerebellar features |
| Autoimmune Autonomic Failure | May be reversible, antibodies present |
| Dopamine β-hydroxylase Deficiency | Pure autonomic failure, norepinephrine very low |
Treatment
Autonomic Symptoms
Orthostatic Hypotension:
-
Fludrocortisone (mineralocorticoid)10Postprandial hypotension in autonomic disorders. Clin Auton Res. 2015Open reference5
-
Midodrine (α-1 agonist)10Postprandial hypotension in autonomic disorders. Clin Auton Res. 2015Open reference6
-
Pyridostigmine (enhances ganglionic transmission)10Postprandial hypotension in autonomic disorders. Clin Auton Res. 2015Open reference7
-
Compression stockings and abdominal binders10Postprandial hypotension in autonomic disorders. Clin Auton Res. 2015Open reference8
-
Increased salt and fluid intake10Postprandial hypotension in autonomic disorders. Clin Auton Res. 2015Open reference9
-
Head-of-bed elevation2Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. Arch Neurol. 1960;2(5):511-527Open reference00
-
Droxidopa (noradrenaline prodrug)2Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. Arch Neurol. 1960;2(5):511-527Open reference01
Supine Hypertension:
-
Bedtime dosing of short-acting agents2Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. Arch Neurol. 1960;2(5):511-527Open reference02
-
Transdermal nitroglycerin2Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. Arch Neurol. 1960;2(5):511-527Open reference03
-
Avoid excessive fluid/salt during day2Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. Arch Neurol. 1960;2(5):511-527Open reference04
Urinary Dysfunction:
-
Intermittent self-catheterization2Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. Arch Neurol. 1960;2(5):511-527Open reference05
-
Anticholinergic medications for detrusor overactivity2Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. Arch Neurol. 1960;2(5):511-527Open reference06
-
Alpha-blockers for outlet resistance2Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. Arch Neurol. 1960;2(5):511-527Open reference07
Gastrointestinal:
-
Stool softeners and laxatives2Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. Arch Neurol. 1960;2(5):511-527Open reference08
-
Prokinetic agents (metoclopramide, domperidone)2Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. Arch Neurol. 1960;2(5):511-527Open reference09
-
Dietary modification2Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. Arch Neurol. 1960;2(5):511-527Open reference10
Motor Symptoms
Parkinsonian Features:
-
Levodopa (often provides limited benefit, 30-50% respond)2Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. Arch Neurol. 1960;2(5):511-527Open reference11
-
Dopamine agonists (pramipexole, ropinirole)2Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. Arch Neurol. 1960;2(5):511-527Open reference12
-
Amantadine (may help gait)2Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. Arch Neurol. 1960;2(5):511-527Open reference13
-
Physical therapy focusing on balance and gait training2Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. Arch Neurol. 1960;2(5):511-527Open reference14
Cerebellar Features:
-
Physical therapy for coordination2Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. Arch Neurol. 1960;2(5):511-527Open reference15
-
Speech therapy for dysarthria2Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. Arch Neurol. 1960;2(5):511-527Open reference16
-
Occupational therapy for ADLs2Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. Arch Neurol. 1960;2(5):511-527Open reference17
Supportive Care
-
Speech therapy for dysphagia and dysarthria2Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. Arch Neurol. 1960;2(5):511-527Open reference18
-
Occupational therapy for daily activities2Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. Arch Neurol. 1960;2(5):511-527Open reference19
-
Psychological support2Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. Arch Neurol. 1960;2(5):511-527Open reference20
-
Sleep study for sleep apnea management2Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. Arch Neurol. 1960;2(5):511-527Open reference21
-
Regular monitoring for complications2Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. Arch Neurol. 1960;2(5):511-527Open reference22
Prognosis
Disease Course:
-
Progressive disease with median survival of 6-9 years from symptom onset2Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. Arch Neurol. 1960;2(5):511-527Open reference23
-
More rapid progression than idiopathic Parkinson’s disease2Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. Arch Neurol. 1960;2(5):511-527Open reference24
-
Mean age of onset: 50-60 years2Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. Arch Neurol. 1960;2(5):511-527Open reference25
Poor Prognostic Factors:
-
Early falls2Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. Arch Neurol. 1960;2(5):511-527Open reference26
-
Rapid disease progression2Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. Arch Neurol. 1960;2(5):511-527Open reference27
-
Cerebellar phenotype may have slightly better prognosis2Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. Arch Neurol. 1960;2(5):511-527Open reference28
-
Poor levodopa response2Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. Arch Neurol. 1960;2(5):511-527Open reference29
Complications:
-
Recurrent falls and fractures2Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. Arch Neurol. 1960;2(5):511-527Open reference30
-
Urinary tract infections2Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. Arch Neurol. 1960;2(5):511-527Open reference31
-
Aspiration pneumonia2Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. Arch Neurol. 1960;2(5):511-527Open reference32
-
Sleep-disordered breathing2Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. Arch Neurol. 1960;2(5):511-527Open reference33
Historical Significance
The description of Shy-Drager syndrome was instrumental in recognizing that parkinsonism could occur with prominent autonomic dysfunction, leading to the broader concept of “multiple system atrophy” that unifies these overlapping phenotypes2Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. Arch Neurol. 1960;2(5):511-527Open reference34. Key contributions include:
-
Recognition of autonomic failure in movement disorders2Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. Arch Neurol. 1960;2(5):511-527Open reference35
-
Definition of clinical phenotypes now incorporated into MSA criteria2Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. Arch Neurol. 1960;2(5):511-527Open reference36
-
Understanding of autonomic nuclei involvement in neurodegenerative disease2Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. Arch Neurol. 1960;2(5):511-527Open reference37
-
Foundation for MSA research including the α-synuclein discovery2Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. Arch Neurol. 1960;2(5):511-527Open reference38
References
- Graham JG, Oppenheimer DR. Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy. J Neurol Neurosurg Psychiatry. 1969
- Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. Arch Neurol. 1960;2(5):511-527
- Shy GM, Drager GA. Original description (1960)
- Bannister R, Oppenheimer DR. Degenerative diseases of the nervous system. Brain. 1972
- Graham JG, Oppenheimer DR. MSA terminology (1989)
- α-Synuclein in filamentous inclusions of MSA. Nature. 1997
- Second consensus statement on MSA. Neurology. 2008
- MSA: autonomic features. Neurol Clin. 2015
- Freeman R. Orthostatic hypotension in MSA. Clin Auton Res. 2008
- Postprandial hypotension in autonomic disorders. Clin Auton Res. 2015
- Supine hypertension in MSA. Auton Neurosci. 2012
- Heart rate variability in MSA. Mov Disord. 2003
- Urinary dysfunction in MSA. J Neurol Neurosurg Psychiatry. 2000
- Bladder dysfunction in MSA. Brain. 1999
- Urodynamic findings in MSA. J Neurol Sci. 1995
- Jost WH. Autonomic bladder in MSA. Eur Urol. 1999
- Sexual dysfunction in MSA. J Neurol. 2000
- Autonomic dysfunction in MSA. Clin Auton Res. 2019
- Gastrointestinal dysfunction in MSA. Ann Neurol. 2002
- Dysphagia in MSA. Mov Disord. 2001
- Gastroparesis in MSA. J Neurol. 1999
- Natural history of MSA. Mov Disord. 2013
- Sweating dysfunction in MSA. J Neurol. 2000
- Thermoregulatory dysfunction in MSA. Clin Auton Res. 2012
- Heat intolerance in autonomic disorders. Auton Neurosci. 2016
- Parkinsonism in MSA. J Neural Transm. 2015
- Bradykinesia in MSA. Mov Disord. 1997
- Rigidity in MSA. Eur Neurol. 1995
- Tremor in MSA. Mov Disord. 1999
- Postural instability in MSA. J Neurol. 2003
- Gait in MSA. Mov Disord. 2017
- Levodopa response in MSA. Brain. 1993
- Symmetry in MSA. Mov Disord. 2002
- Progression in MSA. Mov Disord. 2013
- Falls in MSA. J Neurol Neurosurg Psychiatry. 1990
- Cerebellar ataxia in MSA. Brain. 1993
- Cerebellar features of MSA. Ann Neurol. 1996
- Limb ataxia in MSA. Brain. 1998
- Speech in MSA. Neurology. 1993
- Oculomotor abnormalities in MSA. J Neurol. 2007
- Eye movements in MSA. Mov Disord. 2008
- Stridor in MSA. Neurology. 2006
- Laryngeal dysfunction in MSA. Laryngoscope. 2011
- Duffy JR. Motor speech disorders in MSA. J Speech Lang Hear Res. 2015
- Sleep apnea in MSA. Ann Neurol. 2006
- REM sleep behavior disorder in MSA. Brain. 2006
- Neuropathology of MSA. Acta Neuropathol. 2012
- Brainstem atrophy in MSA. Neurology. 2006
- Cerebellar pathology in MSA. J Neurol Sci. 2002
- Putaminal lesion in MSA. Neuroradiology. 1994
- Jellinger KA. Nigrostriatal involvement in MSA. J Neural Transm. 1996
- Autonomic nuclei in MSA. Brain. 1999
- Dorsal vagal nucleus in MSA. Ann Neurol. 1995
- Nucleus tractus solitarius in MSA. Clin Neuropathol. 1996
- Onuf's nucleus in MSA. J Neurol Neurosurg Psychiatry. 1997
- IML column in MSA. Clin Neuropathol. 1997
- α-Synuclein in GCIs. Nature. 1997;388(6645):839-840
- Glial inclusions in MSA. Acta Neuropathol. 2005
- Catecholamines in MSA. Neurology. 2000
- Dopamine in MSA. J Neurol Transm. 1998
- Sandyk R. Serotonin in MSA. J Neurol. 1984
- GABA in MSA. J Neurol Sci. 1990
- Baroreflex in MSA. Ann Neurol. 1992
- Locus coeruleus in MSA. Clin Neuropathol. 1999
- Plasma catecholamines in MSA. Clin Auton Res. 1997
- Genetics of MSA. Nat Rev Neurol. 2019
- Consensus criteria for MSA. Neurology. 2008;71(9):670-676
- MSA terminology. Mov Disord. 2013
- Kovacs GG. α-Synuclein in MSA. Acta Neuropathol. 2016
- MSA diagnostic criteria. J Parkinsons Dis. 2024
- Mixed phenotype MSA. Brain. 2019
- MSA-A (Shy-Drager). Mov Disord. 2013
- GCI pathology. Nature. 1997;388(6645):839-840
- Oligodendrogliopathy in MSA. Nat Rev Neurol. 2022
- Distribution of pathology in MSA. J Neuropathol Exp Neurol. 2016
- MSA subtypes overlap. Brain. 1999
- Autonomic failure in MSA-P. Mov Disord. 2014
- Parkinsonism in MSA-A. J Neurol. 1998
- Second consensus criteria. Neurology. 2008;71(9):670-676
- MSA pathology criteria. Acta Neuropathol. 2012;124(1):1-16
- Autonomic failure criteria. Clin Auton Res. 2022
- Probable MSA diagnosis. J Neurol Sci. 2020
- Possible MSA. Mov Disord. 2013
- MRI in MSA. J Neurol. 2023
- MRI atrophy patterns in MSA. J Neurol. 2001
- Hot cross bun sign in MSA. J Neurol Sci. 2002
- Putaminal MRI in MSA. Neurology. 2002
- DWI in MSA. Neurology. 2007
- DAT imaging in MSA. Mov Disord. 2003
- Baroreflex testing. Clin Auton Res. 2019
- Heart rate variability. Mov Disord. 2003;18(8):871-878
- Thermoregulatory sweat test. Neurology. 2006
- Urodynamic testing in MSA. Nat Rev Urol. 2019
- CSF biomarkers in MSA. J Neurol. 2023
- Plasma catecholamines in [autonomic failure](/mechanisms/autonomic-dysfunction-neurodegeneration). Clin Auton Res. 1997;7(1):3-7
- Fludrocortisone in OH. Neurology. 2005
- Midodrine in OH. Neurology. 1993
- Pyridostigmine in OH. Neurology. 1991
- Compression therapy in OH. Clin Auton Res. 2009
- Fluid and salt therapy in OH. Auton Neurosci. 2000
- Bed head elevation in OH. Lancet. 1994
- Droxidopa for OH. N Engl J Med. 2013
- Supine hypertension management. Hypertension. 2007
- Transdermal nitroglycerin for supine HTN. Hypertension. 2000
- Management of supine HTN. Clin Auton Res. 2019
- Catheterization in neurogenic bladder. Neurourol Urodyn. 2019
- Anticholinergics in neurogenic OAB. Prog Urol. 2019
- Alpha-blockers in MSA. Mov Disord. 2002
- Constipation in autonomic disorders. Nat Rev Gastroenterol Hepatol. 2009
- Prokinetics in gastroparesis. Mov Disord. 2002
- Dietary management in MSA. Mov Disord. 2008
- Levodopa in MSA. Brain. 1995
- Dopamine agonists in MSA. Mov Disord. 1999
- Amantadine in MSA. Clin Neuropharmacol. 1998
- Physical therapy in MSA. Eur J Phys Rehabil Med. 2015
- Physical therapy in cerebellar ataxia. Phys Ther. 1980
- Speech therapy in neurodegenerative disease. Folia Phoniatr Logop. 2007
- Occupational therapy in parkinsonism. Parkinsonism Relat Disord. 2014
- Speech therapy in neurogenic speech disorders. J Commun Disord. 2001
- OT in autonomic disorders. Occup Ther Health Care. 2014
- Psychological aspects of MSA. Mov Disord. 2014
- Sleep disorders in MSA. Sleep Med Rev. 2010
- Monitoring in MSA. Nat Rev Neurol. 2013
- Survival in MSA. Brain. 1997
- Comparison of survival MSA vs PD. Mov Disord. 1999
- Age of onset in MSA. Mov Disord. 1999
- Prognostic factors in MSA. J Neurol Neurosurg Psychiatry. 1990
- Prognostic markers in MSA. Mov Disord. 2002
- MSA-C vs MSA-P prognosis. Neurology. 2002
- Levodopa response predicts prognosis. Mov Disord. 2018
- Falls in MSA. Mov Disord. 2001
- Urinary complications in MSA. Mov Disord. 2000
- Aspiration in MSA. Dysphagia. 2008
- Sleep apnea and MSA. Sleep Med. 2019
- Shy GM, Drager GA. Historical significance. Arch Neurol. 1960
- Bannister R. Autonomic failure in movement disorders. Brain. 1988
- Historical development of MSA criteria. Neurology. 2008
- Autonomic nuclei pathology. Brain. 1999
- α-Synuclein discovery impact. Nature. 1997
Sister wikis (recently updated · no domain on this page)
- Agent Recipe: AI-for-Biology Closed-Loop with Reviewer Handoffs and Eval Contracts
- Agent Recipe: AI-for-Biology Closed-Loop with Reviewer Handoffs and Eval Contracts
- test
- JGBO-I27: Top 10 GBO Questions for Prioritization
- JGBO-I27: Top 10 GBO Questions for Prioritization
- Design Brief: Beta-test Evaluation Protocol for SciDEX v2 Design Trajectories
- Andy — Showcase Findings (auto-curated)
- Kris — Showcase Findings (auto-curated)
Recent activity here
No recent events touching this page.